- Comprehensive results from the investigator led trial of bemcentininb + docetaxel in previously treated NSCLC patients (Study BGBIL005) were published in the
August 2023 issue ofLung Cancer . "Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer."Lung Cancer 182 (2023) The trial was led byDavid Gerber , MD., Professor at theUT Southwestern Harold C. Simmons Comprehensive Cancer Center . -
The abstract "Bemcentinib + Pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: Exploratory sub-analysis from the BGBC008 trial (NCT03184571)" has been accepted for poster presentation at the SITC 38th Annual Meeting, to be held
November 3-5, 2023 , inSan Diego, CA (Abstract #598). -
The abstract "Final top-line results of the BGBC008 phase 2, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in 2nd line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)" has been accepted for poster presentation at the
ESMO Congress 2023, to be heldOctober 20-24, 2023 , inMadrid, Spain (Abstract #5343)
"The accumulating evidence supporting the potential role of bemcentinib in NSCLC aligns with our strategic focus on this disease where a large portion of patients still have very poor clinical outcome from existing therapies" said
-End-
Contacts
ir@bergenbio.com
rune.skeie@bergenbio.com
Media Relations
jl@lillebyfrisch.no
+47 90 55 16 98
About
This information is subject to the disclosure requirements pursuant to MAR article 17 and section 5-12 of the Norwegian Securities Trading Act.
https://news.cision.com/bergenbio-asa/r/bergenbio-announces-clinical-data-presentations-highlighting-the-activity-of-its-selective-axl-inhib,c3821248
(c) 2023 Cision. All rights reserved., source